Investor Dashboard

Developing two novel drugs to improving the lives of people with neurodevelopmental disabilities, with potential for first US marketing approval in Q1 2023.

Latest Announcements

Read More >>

Annual & Interim Reports

Read More >>

Annual Reports

Presentations

Factsheet

Subscribe to our Email Alerts

Sign up to our email alerts to get the latest news and updates delivered directly in your inbox.